drugset / Trial / NCT00389064

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

NCT00389064

Phase 3 Completed 450 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder. PLEASE NOTE: Seroquel SR and Seroquel extended release(XR) refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Timeline

Start
2006-09
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 50 mg
Subject Quetiapine Small molecule 300 mg